Anixa Biosciences (ANIX) investor relations material

Management strategy and operational model

• Operates with a lean team of four employees, leveraging partnerships with Cleveland Clinic and Moffitt Cancer Center, and consultants for clinical trials and manufacturing.

• Focuses on capital preservation by minimizing cash burn and dilution, advancing programs through strategic partnerships.

• Board members and management are highly invested, holding significant stock positions.

Clinical program updates and differentiation

• CAR-T program for ovarian cancer targets FSHR, showing promising efficacy and significant life extension in terminal patients, with one patient surviving over two years.

• Early data indicate superior results compared to other solid tumor CAR-T trials, with local delivery into the peritoneum and a unique target.

• Next cohort will increase dosage and introduce lymphodepletion to enhance T-cell engraftment and potency.

• Overall survival is the primary endpoint, with tumor necrosis and T-cell infiltration observed.

Breast cancer vaccine program and strategy

• Vaccine designed for both therapeutic and prophylactic use, initially targeting neoadjuvant setting in combination with KEYTRUDA.

• Combination with KEYTRUDA did not increase side effects, supporting further development in this setting.

• Long-term goal is to develop the vaccine as a solo agent for recurrence prevention and ultimately as a prophylactic for healthy individuals.

• Off-the-shelf peptide vaccine offers cost and access advantages over personalized mRNA approaches.